Healthcare is the clearest large-industry example of governance becoming reusable decision evidence: authorisation, lifecycle records and formal product files make the position easier to buy, defend and scale.
Evidence becomes part of the operating advantage
Healthcare resolves to B across 103 assessed systems, with mean public-evidence coverage of 82.3%. Fifty-one positions sit at T≥90 and 12 healthcare systems are in the A zone. Authorisation routes create durable records that buyers, boards and authorities can reconstruct after the decision.
The discipline travels beyond clinical products
The same organisation can extend authorisation-grade evidence discipline to commercial, workforce, supply-chain, pharmacovigilance and enterprise AI. The commercial gain is practical: faster procurement, stronger tender credibility, cleaner expansion decisions and evidence that can be reused when scrutiny arrives.
Decision questions
Where in our non-clinical AI estate are we accepting a lower evidence standard than we already require for regulated products?
Which product, version and site evidence must remain current after approval?
Which evidence can be reused across procurement, expansion, board approval and authority response?
The board test
Which parts of the AI estate would become easier to approve, buy or scale if they inherited the evidence discipline already normal in the clinical portfolio?
Method: RATE AI Public White Paper v2.1.